SCHEMBL2016865

SCHEMBL2016865

Fc1cccc(-c2c(CCNc3ncnc4[nH]cnc34)cc(Cl)c3ccnnc23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.56
BCL2 P10415 1/20 0.48
MAP4K4 O95819 4/20 0.36
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
PIK3CG P48736 1/20 0.34
CLK4 Q9HAZ1 2/20 0.34
AURKA O14965 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
PRKD3 O94806 1/20 0.34
PAK4 O96013 1/20 0.34
ABL1 P00519 1/20 0.34
LCK P06239 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
FGFR1 P11362 1/20 0.34
PRKACA P17612 1/20 0.34
FLT1 P17948 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2051059 0.95 PIK3CD (0.53) PIK3CDBCL2MAP4K4AXLMERTK
SCHEMBL2012486 0.92 PIK3CD (0.46) PIK3CDBCL2LMNAMAPK1HTT
SCHEMBL2012713 0.91 PIK3CD (0.55) PIK3CDBCL2MAP4K4AXLMERTK
SCHEMBL2016719 0.91 PIK3CD (0.47) PIK3CDBCL2MAP4K4AXLMERTK
SCHEMBL2052089 0.90 PIK3CD (0.48) PIK3CDBCL2MAP4K4AXLMERTK
SCHEMBL2016210 0.90 PIK3CD (0.55) PIK3CDBCL2MAP4K4AXLMERTK
SCHEMBL2051140 0.87 PIK3CD (0.45) PIK3CDBCL2MAP4K4AXLMERTK
Trifluoroacetic Acid SCHEMBL2038097 0.85 PIK3CD (0.49) PIK3CDBCL2MAP4K4PIK3CGCLK4
SCHEMBL2050306 0.85 PIK3CD (0.42) PIK3CDBCL2CLK4AURKADYRK1A
SCHEMBL2012817 0.84 PIK3CD (0.42) PIK3CDBCL2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3129021-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR Incyte Corporation (US) 2017-02-15 EP claimed
WO-2015157257-A1 TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITOR INCYTE CORPORATION (US) 2015-10-15 WO claimed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed